← Back to Home

Replacing Monthly Intraocular Injections With Refills Every Six Months: European Medicines Review Backs Implant Therapy for Wet Macular Degeneration

Susvimo continuously releases ranibizumab through a refillable intraocular implant and could substantially reduce treatment frequency; however, it requires ophthalmic surgery and is limited to adults whose condition has stabilized after prior anti-VEGF treatment.

By SURL BioNews

The challenge of treating wet age-related macular degeneration often lies not only in whether a drug is effective, but also in whether patients can endure frequent intraocular injections over many years. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has now recommended the approval of Susvimo, seeking to extend a regimen of injections every four weeks to treatment once every six months through a refillable intraocular implant.

The CHMP adopted a positive opinion on July 23, 2026, and Susvimo was one of 12 new medicines supported at that meeting. The opinion does not yet constitute formal marketing authorization; a decision must still be made by the European Commission. The applicant is Roche Registration GmbH.

Susvimo is a 100 mg/mL ranibizumab solution that is continuously released into the vitreous through the Contivue intraocular implant. Ranibizumab inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the macula. The difference lies not in the drug’s mechanism of action, but in replacing repeated injections with a long-acting, refillable delivery system.

The randomized phase 3 study supporting the review enrolled 415 patients, with outcomes assessed by masked visual acuity evaluators. The study showed that treatment involving an implant refill every 24 weeks was comparable with intravitreal ranibizumab injections every four weeks in maintaining vision and ocular anatomical outcomes. The available data support comparable efficacy and reduced treatment frequency, rather than demonstrating that the implant delivers better vision.

The approval recommendation also sets clear boundaries: it applies to adults with wet macular degeneration who previously responded to an intravitreal VEGF inhibitor and whose condition has stabilized. In other words, it is not an alternative that can be used immediately by all newly diagnosed patients, nor should “once every six months” be taken to mean that continued follow-up is unnecessary.

Fewer injections also introduce new procedural burdens. The implant must be surgically inserted and managed by an ophthalmologist with experience in vitreoretinal surgery who has received training in the relevant procedures. Common adverse reactions listed by the EMA include iritis, conjunctival bleb or leakage, cataract, floaters, conjunctival hemorrhage and hyperemia, eye pain, and headache.

If the European Commission ultimately grants approval, Susvimo will offer not an entirely new anti-VEGF molecule, but another way to organize treatment for a chronic eye disease. It may reduce the burden caused by frequent clinic visits for injections, but its practical value will still depend on surgical risks, implant care, patient selection, and whether efficacy and safety can be maintained consistently during long-term use.

References

  1. European Medicines Agency
  2. European Medicines Agency
  3. European Medicines Agency